Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study. J of Skin. 2023;7(2):s153. doi:10.25251/skin.7.supp.153